{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:06:06Z","timestamp":1774490766334,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106064","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:05:49Z","timestamp":1772467549000},"page":"106064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-3923","authenticated-orcid":false,"given":"L.","family":"Boscolo Bielo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"D.","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-8053","authenticated-orcid":false,"given":"S.","family":"Chandarlapaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.esmoop.2026.106064_bib1","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106064_bib2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106064_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2\u2212 early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106064_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.esmoop.2026.106064_bib5","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106064_bib6","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106064_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamaoncol.2017.5524","article-title":"Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer","volume":"4","author":"Sestak","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106064_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw149","article-title":"Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy","volume":"108","author":"Buus","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106064_bib9","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2\u2212 breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106064_bib10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","article-title":"The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer","volume":"20","author":"Filipits","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"suppl 9","key":"10.1016\/j.esmoop.2026.106064_bib11","first-page":"GS03","article-title":"Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2\u2212, node-positive, high-risk early breast cancer in the monarchE trial","volume":"84","author":"Turner","year":"2024","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106064_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106064_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41523-024-00670-2","article-title":"Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers","volume":"10","author":"Hilbers","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106064_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-024-00883-1","article-title":"Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma","volume":"6","author":"Biswas","year":"2025","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106064_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2024.06.010","article-title":"Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma","volume":"35","author":"Fraunhoffer","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106064_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106064_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-021-01633-1","article-title":"Artificial intelligence in oncology: current applications and future perspectives","volume":"126","author":"Luchini","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106064_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"issue":"269","key":"10.1016\/j.esmoop.2026.106064_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.esmoop.2026.106064_bib20","article-title":"The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.106064_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102501","article-title":"Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials","volume":"70","author":"Blondeaux","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106064_bib22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2006.07.1522","article-title":"Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade","volume":"25","author":"Loi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106064_bib23","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","article-title":"GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor","volume":"23","author":"Davis","year":"2007","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106064_bib24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ccr.2006.10.009","article-title":"Genomic and transcriptional aberrations linked to breast cancer pathophysiologies","volume":"10","author":"Chin","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2026.106064_bib25","article-title":"Gene expression profile analysis of T1 and T2 breast cancer reveals different activation pathways","volume":"2013","author":"Riis","year":"2013","journal-title":"ISRN Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106064_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-007-9673-x","article-title":"Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen","volume":"109","author":"Campone","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106064_bib27","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-14-3706","article-title":"Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer","volume":"75","author":"Cunha","year":"2015","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106064_bib28","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1158\/0008-5472.CAN-07-5206","article-title":"The humoral immune system has a key prognostic impact in node-negative breast cancer","volume":"68","author":"Schmidt","year":"2008","journal-title":"Cancer Res"},{"issue":"7050","key":"10.1016\/j.esmoop.2026.106064_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature03799","article-title":"Genes that mediate breast cancer metastasis to lung","volume":"436","author":"Minn","year":"2005","journal-title":"Nature"},{"issue":"38","key":"10.1016\/j.esmoop.2026.106064_bib30","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1073\/pnas.0506230102","article-title":"An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival","volume":"102","author":"Miller","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106064_bib31","doi-asserted-by":"crossref","first-page":"8770","DOI":"10.1038\/s41598-019-45165-4","article-title":"MetaGxData: clinically annotated breast, ovarian and pancreatic cancer datasets and their use in generating a multi-cancer gene signature","volume":"9","author":"Gendoo","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106064_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12859-023-05578-5","article-title":"pyComBat, a Python tool for batch effects correction in high-throughput molecular data using empirical Bayes methods","volume":"24","author":"Behdenna","year":"2003","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106064_bib33","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jmoldx.2021.04.011","article-title":"Clinical validation of whole genome sequencing for cancer diagnostics","volume":"23","author":"Roepman","year":"2021","journal-title":"J Mol Diagn"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106064_bib38","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","article-title":"Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer","volume":"32","author":"Gendoo","year":"2016","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106064_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2026.106064_bib40","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","article-title":"A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors","volume":"17","author":"Filipits","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106064_bib41","first-page":"2825","article-title":"Scikit-learn: machine learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"key":"10.1016\/j.esmoop.2026.106064_bib42","first-page":"1","article-title":"Scikit-survival: a library for time-to-event analysis built on top of scikit-learn","volume":"21","author":"P\u00f6lsterl","year":"2020","journal-title":"J Mach Learn Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106064_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btac757","article-title":"GSEApy: a comprehensive package for performing gene set enrichment analysis in Python","volume":"39","author":"Fang","year":"2023","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106064_bib44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106064_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106064_bib46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"Database issue","key":"10.1016\/j.esmoop.2026.106064_bib47","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.esmoop.2026.106064_bib48","author":"Gerds"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106064_bib58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01840834","article-title":"The Nottingham Prognostic Index in primary breast cancer","volume":"22","author":"Galea","year":"1992","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106064_bib60","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1200\/JCO.2022.40.16_suppl.1010","article-title":"Allelic dosage of RB1 drives CDK4\/6 inhibitor treatment resistance in metastatic breast cancer","volume":"40","author":"Safonov","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106064_bib61","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-019-05226-8","article-title":"Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone","volume":"176","author":"Sestak","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106064_bib62","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2015.62.6630","volume":"34","author":"Wolmark","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106064_bib63","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(23)00165-1","article-title":"Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer","volume":"24","author":"Meirson","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.106064_bib64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106064_bib65","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106064_bib66","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2022.1488","article-title":"Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy","volume":"8","author":"Martin","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106064_bib67","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106064_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113198","article-title":"Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106064_bib69","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106064_bib70","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106064_bib71","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/bjc.2016.359","article-title":"The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients","volume":"115","author":"Lambertini","year":"2016","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106064_bib72","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6605283","article-title":"An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom","volume":"101","author":"Campbell","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.106064_bib73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.03.015","article-title":"Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years","volume":"78","author":"Engelhardt","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:16:12Z","timestamp":1774487772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000062"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106064","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106064"}}